Octreotide for advanced neuroendocrine tumors
Part of Cancer clinical trials.
This study looks at how well octreotide microspheres work in Chinese patients with neuroendocrine tumors that cannot be removed by surgery or have spread. It aims to see if this treatment helps control the disease in real-world settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a neuroendocrine tumor that cannot be surgically removed or has spread to other parts of the body.
- Your tumor has come back or grown after previous surgery or local treatment.
- You are 18 years old or older.
- You are planning to receive or are currently receiving octreotide microspheres.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This study tests a new type of PET scan that uses a special tracer (a radioactive substance) to find neuroendocrine tumors. The scan may help detect these tumors more clearly, which can guide treatment decisions.
This trial is testing an injectable medicine called octreotide for people with advanced neuroendocrine tumors of the digestive system or pancreas. It aims to see if the medicine can help control the tumor.
This trial tests a combination of two drugs, sirolimus and octreotide, for people with advanced neuroendocrine tumors in the digestive system that cannot be removed by surgery and are not making excess hormones. The goal is to see if this combination can help control the tumors.
This trial tests a radioactive drug called [177Lu]Lu-DOTA-TATE for people with advanced neuroendocrine tumors (GEP-NET) that have grown or spread. The drug targets tumor cells that have a specific receptor (SSTR) and delivers radiation directly to them, aiming to slow or shrink the tumors while limiting damage to healthy tissue.
Hear when a new Neuroendocrine Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.